| Primary |
| Unevaluable Event |
36.3% |
| Pulmonary Tuberculosis |
11.3% |
| Osteitis |
10.8% |
| Drug Use For Unknown Indication |
5.2% |
| Lung Disorder |
4.7% |
| Pneumonia |
4.2% |
| Tuberculosis |
3.8% |
| Bronchitis |
3.3% |
| Diabetes Mellitus Non-insulin-dependent |
2.8% |
| Essential Hypertension |
2.8% |
| Sinusitis |
2.8% |
| Hiv Infection |
1.9% |
| Superinfection Lung |
1.9% |
| Aspergillosis |
1.4% |
| Depression |
1.4% |
| Mycobacterial Infection |
1.4% |
| Arthropathy |
0.9% |
| Bronchopneumonia |
0.9% |
| Cellulitis |
0.9% |
| Cytomegalovirus Infection |
0.9% |
|
| Visual Acuity Reduced |
8.6% |
| Weight Decreased |
8.6% |
| Clostridium Difficile Colitis |
5.7% |
| Cytolytic Hepatitis |
5.7% |
| Drug Eruption |
5.7% |
| Hyperkalaemia |
5.7% |
| Polymyositis |
5.7% |
| Purpura |
5.7% |
| Pyrexia |
5.7% |
| Throat Irritation |
5.7% |
| Toxic Epidermal Necrolysis |
5.7% |
| Vascular Purpura |
5.7% |
| Vomiting |
5.7% |
| Arrhythmia |
2.9% |
| Eye Pain |
2.9% |
| Haemoglobin Decreased |
2.9% |
| Headache |
2.9% |
| Hepatitis Cholestatic |
2.9% |
| Hypoglycaemia |
2.9% |
| Idiopathic Thrombocytopenic Purpura |
2.9% |
|
| Secondary |
| Product Used For Unknown Indication |
17.1% |
| Drug Use For Unknown Indication |
15.8% |
| Pulmonary Tuberculosis |
8.1% |
| Bronchitis |
7.7% |
| Hypertension |
6.4% |
| Tuberculosis |
6.2% |
| Unevaluable Event |
6.2% |
| Hiv Infection |
5.6% |
| Osteitis |
4.4% |
| Pneumonia |
3.7% |
| Attention Deficit/hyperactivity Disorder |
3.5% |
| Hiv Test Positive |
2.9% |
| Bronchitis Acute |
2.3% |
| Bronchopneumonia |
1.7% |
| Chronic Obstructive Pulmonary Disease |
1.5% |
| Pain |
1.5% |
| Cytomegalovirus Infection |
1.3% |
| Diarrhoea |
1.3% |
| Muscle Spasms |
1.3% |
| Respiratory Tract Infection |
1.3% |
|
| Pyrexia |
11.8% |
| Renal Failure |
10.3% |
| Vomiting |
10.3% |
| Tendon Pain |
7.4% |
| Thrombocytopenia |
7.4% |
| Vestibular Disorder |
7.4% |
| Electrocardiogram Qt Prolonged |
5.9% |
| Drug Hypersensitivity |
4.4% |
| Hyperkalaemia |
4.4% |
| Thrombocytopenic Purpura |
4.4% |
| Idiopathic Thrombocytopenic Purpura |
2.9% |
| Multi-organ Failure |
2.9% |
| Polymyositis |
2.9% |
| Sepsis |
2.9% |
| Toxic Epidermal Necrolysis |
2.9% |
| Viith Nerve Paralysis |
2.9% |
| Weight Decreased |
2.9% |
| White Blood Cell Count Decreased |
2.9% |
| Anaphylactic Reaction |
1.5% |
| Blood Magnesium Decreased |
1.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
31.5% |
| Drug Use For Unknown Indication |
11.4% |
| Prophylaxis |
7.2% |
| Hiv Infection |
5.1% |
| Macular Degeneration |
4.7% |
| Pyrexia |
4.3% |
| Age-related Macular Degeneration |
3.8% |
| Bone Marrow Conditioning Regimen |
3.7% |
| Rheumatoid Arthritis |
3.6% |
| Infection Prophylaxis |
3.0% |
| Hypertension |
2.9% |
| Premedication |
2.5% |
| Acute Myeloid Leukaemia |
2.4% |
| Gastritis Prophylaxis |
2.4% |
| Prophylaxis Against Graft Versus Host Disease |
2.4% |
| Chronic Obstructive Pulmonary Disease |
2.1% |
| Tuberculosis |
2.1% |
| Atypical Mycobacterial Infection |
2.0% |
| Prophylaxis Of Nausea And Vomiting |
1.6% |
| Adverse Event |
1.5% |
|
| Pyrexia |
13.2% |
| Vomiting |
13.2% |
| Retinal Haemorrhage |
7.9% |
| Interstitial Lung Disease |
7.0% |
| Weight Decreased |
5.3% |
| Renal Failure |
4.4% |
| Visual Acuity Reduced |
4.4% |
| Vitreous Haemorrhage |
4.4% |
| White Blood Cell Count Decreased |
4.4% |
| Haemoglobin Decreased |
3.5% |
| Hepatitis B |
3.5% |
| Incontinence |
3.5% |
| Intraocular Pressure Increased |
3.5% |
| Lacunar Infarction |
3.5% |
| Pulmonary Embolism |
3.5% |
| Skin Exfoliation |
3.5% |
| Vision Blurred |
3.5% |
| Cataract |
2.6% |
| Cerebellar Infarction |
2.6% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
30.4% |
| Unevaluable Event |
21.4% |
| Rheumatoid Arthritis |
16.1% |
| Helicobacter Gastritis |
10.7% |
| Implant Site Thrombosis |
10.7% |
| Bronchitis |
3.6% |
| Respiratory Tract Infection |
3.6% |
| Urinary Tract Infection |
3.6% |
|
| Prothrombin Level Decreased |
42.9% |
| Clostridium Difficile Colitis |
28.6% |
| Haemorrhage |
14.3% |
| Hypersensitivity |
14.3% |
|
